CompletedNot Applicable

Ameparomo Capsules 250 mg Drug Use Investigation

120 participantsStarted 2015-10-19

Plain-language summary

This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

Age range15 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with no history of using this product Exclusion Criteria: * No exclusion criteria are set out in this study.

Number of Participants With Adverse Drug Reactions

Timeframe: 38 days at maximum

NCT IDNCT02680665

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-12-21

Results submitted2019-12-11